Added to YB: 2025-10-07
Pitch date: 2025-10-04
SLNO [bullish]
Soleno Therapeutics, Inc.
-11.95%
current return
Author Info
No bio for this author
Company Info
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Market Cap
$2.8B
Pitch Price
$60.18
Price Target
100.00 (+89%)
Dividend
N/A
EV/EBITDA
24.71
P/E
29.97
EV/Sales
8.02
Sector
Biotechnology
Category
growth
Soleno Therapeutics, Inc. Long Idea
SLNO: Only FDA-approved therapy for Prader-Willi hyperphagia, ~$500K/year pricing. Strong launch: Q2 $32.7M revenue vs consensus, 1000+ treatments initiated. Peak sales $1.8B-$2.6B target. Safety concerns overblown vs 3-4% natural PWS mortality. $100 price target in 12-18mo if Q3 beats $46M consensus.
Read full article (2 min)